Ricardo Leyva
Family · McKinney, TXNPI 1427436849
Payments from drug & device makers
Across 611 payments — averaging $16.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Lilly USA, LLC$967
- Bayer$932
- Takeda Pharmaceuticals U.S.A., Inc.$700
- GSK$610
- AbbVie$595
- plus $6K from 32 others
What the payments were for
- Food & beverage$10,27299%
- Education$1111%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 74 | $1,055 |
| Lilly USA, LLC | 57 | $967 |
| Bayer | 55 | $932 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $700 |
| GSK | 36 | $610 |
| AbbVie | 33 | $595 |
| Pfizer | 33 | $570 |
| Johnson & Johnson | 34 | $515 |
| AstraZeneca | 28 | $503 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 33 | $450 |
| Novo Nordisk | 22 | $411 |
| Boehringer Ingelheim | 21 | $372 |
| Merck | 20 | $367 |
| Ardelyx, Inc. | 13 | $317 |
| Radius Health, Inc. | 18 | $308 |
| Amarin Pharma, Inc. | 11 | $198 |
| E.r. Squibb & Sons, L.L.C. | 9 | $176 |
| Sanofi-aventis U.S. LLC | 10 | $154 |
| Astellas Pharma US Inc | 6 | $150 |
| Nestle Healthcare Nutrition Inc. | 8 | $148 |
| Exact Sciences | 8 | $124 |
| Abbott | 6 | $121 |
| Aimmune Therapeutics, Inc. | 5 | $99 |
| Sumitomo Pharma America, Inc. | 5 | $98 |
| Kowa Pharmaceuticals America, Inc. | 6 | $85 |
| Novartis | 3 | $58 |
| Eisai Inc. | 3 | $57 |
| Biogen | 3 | $53 |
| Idorsia Pharmaceuticals US Inc | 3 | $47 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $18 |
| Dexcom, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$10,383 in reported general payments places this provider in the 95th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 129 | $207,278 |
| MounjaroTirzepatide | 158 | $191,009 |
| JardianceEmpagliflozin | 131 | $160,377 |
| FarxigaDapagliflozin Propanediol | 140 | $147,208 |
| TrulicityDulaglutide | 102 | $136,873 |
| ProliaDenosumab | 74 | $130,742 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 107 | $124,483 |
| TradjentaLinagliptin | 107 | $112,971 |
| LinzessLinaclotide | 104 | $97,798 |
| VascepaIcosapent Ethyl | 129 | $88,541 |
| GemtesaVibegron | 107 | $87,518 |
| EliquisApixaban | 71 | $81,474 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 72 | $67,630 |
| MyrbetriqMirabegron | 70 | $66,940 |
| JanuviaSitagliptin Phosphate | 42 | $51,463 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $967 | $327,882260 claims |
| Boehringer IngelheimJardiance, Tradjenta | $372 | $273,347238 claims |
| Novo NordiskOzempic | $411 | $207,278129 claims |
| AstraZenecaFarxiga, Brilinta | $503 | $152,508151 claims |
| AmgenProlia | $1,055 | $130,74274 claims |
| AbbVieLinzess, Synthroid | $595 | $101,984145 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $98 | $87,518107 claims |
| PfizerEliquis | $570 | $81,47471 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $154 | $67,63072 claims |
| Astellas Pharma US IncMyrbetriq | $150 | $66,94070 claims |
| MerckJanuvia | $367 | $51,46342 claims |
| NovartisEntresto | $58 | $50,85233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 15,456 family providers in Texas.
Other family in McKinney
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.